Brought to you by 
Bayer and Schering-Plough in marketing alliance
Sep 2004
Executive Summary
As part of its corporate restructuring, Bayer AG has licensed Schering-Plough exclusive US and Puerto Rican marketing and distribution rights to all the primary care pharma products of its US subsidiary Bayer HealthCare. In turn, S-P has licensed Bayer Japanese co-promotion rights to its cholesterol absorption inhibitor Zetia (ezetimibe), which is currently under review for CV disorders (if approved, Bayer Yakuhin will market it).
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Product or Technology Swap
- Marketing-Licensing
- Co-Promotion
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer and Schering-Plough in marketing alliance
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice